News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
613,167 Results
Type
Article (36960)
Company Profile (129)
Press Release (576078)
Section
Business (172614)
Career Advice (2740)
Deals (32378)
Drug Delivery (81)
Drug Development (72952)
Employer Resources (156)
FDA (15585)
Job Trends (14504)
News (300473)
Policy (29021)
Tag
Academia (2647)
Alliances (43099)
Alzheimer's disease (1321)
Approvals (15551)
Artificial intelligence (158)
Bankruptcy (282)
Best Places to Work (12062)
Breast cancer (200)
Cancer (1481)
Cardiovascular disease (118)
Career advice (2268)
CAR-T (108)
Cell therapy (318)
Clinical research (58689)
Collaboration (566)
Compensation (304)
COVID-19 (2428)
C-suite (139)
Data (1489)
Diabetes (180)
Diagnostics (6438)
Earnings (66825)
Employer resources (137)
Events (100334)
Executive appointments (489)
FDA (16358)
Funding (502)
Gene therapy (216)
GLP-1 (522)
Government (3992)
Healthcare (19761)
Infectious disease (2519)
Inflammatory bowel disease (118)
Interviews (538)
IPO (16078)
Job creations (2876)
Job search strategy (1888)
Layoffs (388)
Legal (6341)
Lung cancer (209)
Manufacturing (203)
Medical device (13856)
Medtech (13861)
Mergers & acquisitions (16643)
Metabolic disorders (421)
Neuroscience (1678)
NextGen: Class of 2025 (6722)
Non-profit (4824)
Northern California (1890)
Obesity (217)
Opinion (209)
Parkinson's disease (109)
Patents (131)
People (51021)
Phase I (18268)
Phase II (26076)
Phase III (19438)
Pipeline (597)
Postmarket research (2024)
Preclinical (7404)
Radiopharmaceuticals (248)
Rare diseases (294)
Real estate (4891)
Regulatory (20187)
Research institute (2434)
Resumes & cover letters (449)
Southern California (1642)
Startups (3050)
United States (16760)
Vaccines (521)
Weight loss (134)
Date
Last 7 days (671)
Last 30 days (1914)
Last 365 days (35536)
2025 (1627)
2024 (36000)
2023 (41331)
2022 (52214)
2021 (57120)
2020 (55639)
2019 (48794)
2018 (36674)
2017 (32209)
2016 (30506)
2015 (35621)
2014 (24895)
2013 (19399)
2012 (20880)
2011 (21661)
2010 (18742)
Location
Africa (756)
Arizona (129)
Asia (35851)
Australia (6384)
California (4236)
Canada (1547)
China (349)
Colorado (192)
Connecticut (211)
Europe (83066)
Florida (604)
Georgia (155)
Illinois (420)
Indiana (242)
Maryland (667)
Massachusetts (3360)
Michigan (201)
Minnesota (315)
New Jersey (1186)
New York (1199)
North Carolina (832)
Northern California (1890)
Ohio (155)
Pennsylvania (1001)
South America (1080)
Southern California (1642)
Texas (614)
Utah (127)
Washington State (432)
613,167 Results for "swedish orphan ab".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Change in number of shares and votes in Swedish Orphan Biovitrum AB (publ) - November 30, 2023
Swedish Orphan Biovitrum AB has, as previously announced, carried out a share issue of series C shares, which has resulted in changes in the number of shares and votes in Sobi.
November 30, 2023
·
1 min read
Change in number of shares and votes in Swedish Orphan Biovitrum AB (publ) - September 29, 2023
Swedish Orphan Biovitrum AB has, as previously announced, carried out a rights issue of common shares, which has resulted in changes in the number of shares and votes in Sobi.
September 29, 2023
·
1 min read
Notice of Extraordinary General Meeting in Swedish Orphan Biovitrum AB (publ)
The shareholders in Swedish Orphan Biovitrum AB Reg. No. 556038-9321, are hereby summoned to the Extraordinary General Meeting, to be held on Tuesday, 15 August 2023 at 10.00 at the offices of Mannheimer Swartling Advokatbyrå, Norrlandsgatan 21, Stockholm, Sweden.
July 18, 2023
·
12 min read
Deals
New number of shares and votes in Swedish Orphan Biovitrum AB (publ) - June 30, 2023
As per 30 June 2023 , the total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi®) amounts to 311,336,796 shares.
June 30, 2023
·
1 min read
Notice of Annual general meeting in Swedish Orphan Biovitrum AB (publ) - March 30, 2023
The shareholders in Swedish Orphan Biovitrum AB Reg. No. 556038-9321, are hereby summoned to the Annual General Meeting, to be held on Tuesday, 9 May 2023 at 15.00 at IVA Konferenscenter, Grev Turegatan 16, Stockholm, Sweden.
March 30, 2023
·
43 min read
New number of shares and votes in Swedish Orphan Biovitrum AB (publ)
As per 30 September 2022, the total number of shares in Swedish Orphan Biovitrum AB amounts to 309,804,782 shares.
September 30, 2022
·
1 min read
Policy
QuTEM Receives GMP Certificates and Manufacturing Permits for Transmission Electron Microscopy Laboratory from the Swedish Medical Products Agency
QuTEM AB, a leading provider of transmission electron microscopy services, proudly announces the receipt of GMP Certificates and Manufacturing Permits for Independent Quality Control Laboratories issued by the Swedish Medical Products Agency.
May 17, 2024
·
3 min read
Business
Sobi Q1 2024 report: Strong sales reflecting the strength of the portfolio
Swedish Orphan Biovitrum AB announced its report for the first quarter 2024.
April 25, 2024
·
3 min read
Bulletin from Sobi’s Annual General Meeting (AGM)
The Swedish Orphan Biovitrum AB AGM was convened on 14 May 2024. At the AGM, the shareholders, in accordance with the proposed resolutions, resolved as follows:.
May 14, 2024
·
3 min read
Drug Development
IRLAB has Received Approval from the Swedish Medical Products Agency to Conduct a Phase I Study of the Drug Candidate IRL757
IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, announced that the Swedish Medical Products Agency has approved the initiation of a Phase I clinical study of the drug candidate IRL757.
May 6, 2024
·
4 min read
1 of 61,317
Next
